Barbara Bralewska

Barbara Bralewska

Auto-generated profile, based on publicly available information

Barbara Bralewska

Central Teaching Hospital of The Medical University of Łódź

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
JGJakub Grandos
Jakub Grandos
MŁMateusz Łaszczych
Mateusz Łaszczych
JNJulia Nowak
Julia Nowak
BBBarbara Bralewska
Barbara Bralewska
JWJulia Wykrota
Julia Wykrota
JJJakub Jonakowski
Jakub Jonakowski
Background. Capsaicin-related compounds, including capsaicin, capsinoids/capsiate, dihydrocapsiate and phenylcapsaicin, are investigated as potential TRPV1-related ergogenic aids, but human exercise evidence remains heterogeneous. Objective. This structured narrative review summarizes human evidence on capsaicin-related compounds in resistance and high-intensity exercise, focusing on performance, rating of perceived exertion (RPE), fatigue, recovery, delayed-onset muscle soreness (DOMS), and selected physiological or neuromuscular outcomes. Methods. A structured PubMed search was supplemented by targeted compound-specific queries. After deduplication and search refinement, 62 unique records were screened by title and Human studies of oral supplementation in resistance, high-intensity, sprint, intermittent, CrossFit-type and recovery-related exercise contexts were prioritized. Findings. Current evidence suggests protocol-specific rather than universal ergogenic effects. Capsaicin showed selected benefits in small male crossover trials involving resistance exercise and high-intensity intermittent exercise, but not in repeated sprinting or continuous high-intensity running. Capsiate and dihydrocapsiate showed mixed findings, with no clear dose-response pattern. Phenylcapsaicin showed preliminary benefits for selected squat, jump, mechanical-performance and soreness-related outcomes, but not consistently for RPE, metabolic markers or whole-session CrossFit Workout-of-the-Day performance. Conclusions. Capsaicin-related compounds may have compound- and protocol-specific ergogenic potential, particularly in selected resistance and intermittent high-intensity settings. However, current evidence is limited by small samples, heterogeneous protocols, inconsistent outcomes and limited independent replication. Larger, well-controlled trials are needed before firm practical recommendations can be made.

28 September 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
JJJakub Jonakowski
Jakub Jonakowski
JGJakub Grandos
Jakub Grandos
JNJulia Nowak
Julia Nowak
MŁMateusz Łaszczych
Mateusz Łaszczych
JWJulia Wykrota
Julia Wykrota
MPMateusz Polak
Mateusz Polak
Background. GLP-1 receptor agonists and related incretin-based therapies reduce appetite, energy intake, and body mass. Their growing use and discussion in sport raise concern about possible interactions with low energy availability, although a direct relationship with Relative Energy Deficiency in Sport (REDs) has not been established. Aim. To evaluate how GLP-1-based therapies may intersect with REDs-relevant pathways in physically active individuals while separating established clinical effects, athlete evidence, and untested inference. Materials and Methods. A structured narrative review used three PubMed/MEDLINE search streams addressing GLP-1 therapies and sport, appetite/body composition/exercise pathways, and REDs or low energy availability. Fifty-five full texts were assessed and the evidence was synthesized thematically. Results. Trials conducted mainly in non-athletic populations show reduced hunger, cravings, and laboratory-measured intake; gastrointestinal effects may further limit food tolerance. Weight loss includes variable reductions in lean-mass indices, but these measures do not establish loss of contractile muscle, strength, or performance. Athlete studies separately associate problematic low energy availability with reproductive, bone, endocrine, injury, and selected performance outcomes. No prospective study has tested progression from GLP-1 exposure to problematic low energy availability and REDs in athletes. Conclusions. GLP-1-based therapy should be considered a potential modifying factor within the REDs framework, not a proven cause. Current evidence supports individualized monitoring of treatment indication, weight trajectory, dietary adequacy, gastrointestinal tolerance, training, recovery, body composition, function, reproductive and bone health, and eating behavior. Athlete-specific prospective studies are required.

24 September 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
BBBarbara Bralewska
Barbara Bralewska
MPMateusz Polak
Mateusz Polak
JNJulia Nowak
Julia Nowak
MŁMateusz Łaszczych
Mateusz Łaszczych
JGJakub Grandos
Jakub Grandos
JWJulia Wykrota
Julia Wykrota
Background: Swimming-induced pulmonary edema (SIPE) is an uncommon but potentially serious complication of open-water swimming and triathlon. For event medical teams, the challenge extends beyond diagnosis to safe extraction, race-side assessment, respiratory support, and decisions about transfer or discharge.Objective: To review the clinical, physiological, and event-medicine literature on SIPE and develop a practical framework for medical care at mass-participation open-water events.Methods: We searched PubMed/MEDLINE and supplemented the search with Google Scholar, Semantic Scholar, Crossref, publisher websites, and citation tracking. Because the review was intended to inform event medicine, studies conducted in mass-participation settings were given greatest weight, with military, diving, physiological, and other clinical literature used when directly relevant.Results: Direct event evidence is concentrated in a small number of overlapping Vansbro cohorts. In symptomatic swimmers, pulse oximetry and auscultation performed well against LUS-confirmed pulmonary edema; at one low-altitude event, SpO₂ ≤95% or crackles gave 97% sensitivity and 86% specificity. These figures are specific to that setting. Lung ultrasound can add useful information, particularly because edema may be focal or anterior. CPAP and PEP have both been used on site with clinical improvement in observational data, but the available observational data do not establish comparative effectiveness. Crackles and B-lines may persist after symptoms and oxygenation improve. Severe, atypical, or non-resolving presentations require escalation.Conclusions: The literature supports a coherent sequence of event care: preparation, recognition, extraction, assessment, supportive treatment, reassessment, and a decision between escalation and stable disposition, followed by handover and follow-up. The framework proposed here is intended as a practical aid for local adaptation, not as a validated clinical protocol.

27 September 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
JNJulia Nowak
Julia Nowak
JGJakub Grandos
Jakub Grandos
MŁMateusz Łaszczych
Mateusz Łaszczych
BBBarbara Bralewska
Barbara Bralewska
JWJulia Wykrota
Julia Wykrota
TNTomasz Nicpoń
Tomasz Nicpoń
Background. Glucagon-like peptide-1 (GLP-1) receptor agonists and related incretin-based therapies can produce substantial weight loss and metabolic benefits. Their effects on objective exercise outcomes are less clear because studies use non-interchangeable endpoints ranging from directly measured oxygen uptake (VO₂) to walking distance. Objective. To summarize objective exercise outcomes during GLP-1-based therapy and separate directly measured cardiorespiratory fitness from changes observed with exercise training and from disease-specific walking capacity. Methods. We searched PubMed and tracked relevant citations up to July 2026. Adult clinical studies reporting at least one objective exercise outcome were grouped by outcome domain. Results. Ten clinical studies were included. In the 193-participant secondary analysis, liraglutide alone did not improve VO₂-derived fitness or physical-performance outcomes. Two smaller trials of exenatide or liraglutide without structured exercise were also neutral. VO₂ improved when structured exercise was included, but comparisons with matched exercise did not establish a clear additive drug effect. Walking outcomes improved most clearly in peripheral artery disease, whereas coronary artery disease and ischemia-focused endpoints were neutral. During substantial weight loss, body-mass-normalized VO₂ may rise partly because body mass in the denominator falls; absolute VO₂, VO₂ normalized to fat-free mass, workload, strength, and body composition therefore require separate interpretation. Conclusions.The meaning of an objective exercise outcome depends on what was measured. Current evidence does not consistently show an independent improvement in directly measured cardiorespiratory fitness with pharmacotherapy alone. Structured exercise remains the best-supported context for improving aerobic fitness. Disease-specific gains in walking capacity should not be interpreted as generalized cardiorespiratory-fitness gains.